Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Evins, A. E. Articles by Goff, D. C. Search for Related Content PubMed Citation Articles by Evins, A. E. Articles by Goff, D. C. Schizophrenia Spectrum Disorders Other Neuroleptics Other Somatic Therapy

Placebo-Controlled Trial of Glycine Added to Clozapine in Schizophrenia

OBJECTIVE: The purpose of this study was to evaluate the effects of high-dose oral glycine on positive and negative symptoms and cognitive function when added to clozapine in adults with schizophrenia.METHOD: The authors conducted a double-blind, placebo-controlled, parallel-group trial of 60 g/day of glycine added to clozapine for 8 weeks in 30 adults with schizophrenia. Clinical ratings were performed every 2 weeks.RESULTS: Twenty-seven patients completed the trial. Glycine augmentation of clozapine produced no statistically significant change in positive or negative symptoms or cognitive functioning. No subjects showed clinically significant worsening of clinical ratings.CONCLUSIONS: These data, combined with data from previous trials with D-cycloserine and glycine, suggest that agonists at the glycine site may be less effective when combined with clozapine than they are when combined with conventional antipsychotics.

This article has been cited by other articles:

				J. A. Gray and B. L. Roth Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia Schizophr Bull, September 1, 2007; 33(5): 1100 - 1119. [Abstract] [Full Text] [PDF]

				R. W Buchanan, M. Davis, D. Goff, M. F Green, R. S E Keefe, A. C Leon, K. H Nuechterlein, T. Laughren, R. Levin, E. Stover, et al. A Summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia Schizophr Bull, January 1, 2005; 31(1): 5 - 19. [Abstract] [Full Text] [PDF]

				U. Heresco-Levy, M. Ermilov, J. Shimoni, B. Shapira, G. Silipo, and D. C. Javitt Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics, Olanzapine, or Risperidone in Schizophrenia Am J Psychiatry, March 1, 2002; 159(3): 480 - 482. [Abstract] [Full Text] [PDF]

				D. C. Goff and J. T. Coyle The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia Am J Psychiatry, September 1, 2001; 158(9): 1367 - 1377. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2000 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us